@inproceedings{705b6ff1b3eb420b9771034658cfcd8d,
title = "Relieving bottlenecks in RNA drug discovery for retinal diseases",
abstract = "The development of efficacious and safe post transcriptional gene silencing (PTGS) agents is a challenging scientific endeavor that embraces {"}biocomplexity{"} at many levels. The target mRNA exhibits a level of structural complexity that profoundly limits annealing of PTGS agents. PTGS agents are macromolecular RNAs that must be designed to fold into catalytically active structures able to cleave the target mRNA. Pushing into and beyond the biological complexity requires new technologies for high throughput screening to efficiently and rapidly assess a set of biological and experimental variables engaged in RNA drug discovery.",
keywords = "Breakthrough Technology Development, Gene Therapy, Hammerhead Ribozyme, High Throughput Screening, Macular Degenerations, Posttranscriptional Gene Silencing, Retinal Degenerations, Ribozyme, shRNA, siRNA",
author = "Sullivan, \{Jack M.\} and Yau, \{Edwin H.\} and Taggart, \{R. Thomas\} and Butler, \{Mark C.\} and Kolniak, \{Tiffany A.\}",
year = "2012",
doi = "10.1007/978-1-4614-0631-0\_20",
language = "English",
isbn = "9781461406303",
series = "Advances in Experimental Medicine and Biology",
pages = "145--153",
editor = "Matthew LaVail and Robert Anderson and Christian Grimm and John Ash and Joe Hollyfield",
booktitle = "Retinal Degenerative Diseases",
}